Six-year PERSEUS results show 81% of newly diagnosed, transplant-eligible myeloma patients had no cancer progression, with many stopping Darzalex.
Related to this article
Ivonescimab outperformed Keytruda, a new myeloma drug lowered progression risk by 60% and more: the biggest phase 3 cancer results of September 2026.
Advertisement
Advertisement
Trending on CURE
1
Epkinly Plus R-CHOP Cuts Lymphoma Progression Risk by 51% in Phase 3 Trial
2
Tumor Traits May Predict Who Responds to Lighter HER2+ Breast Cancer Chemo
3
A Light-Based Treatment Is Now FDA Approved for a Common Skin Cancer
4
Swapping Chemo for Blincyto Helped More Kids With High-Risk Leukemia
5